A retrospective study of patients with metastatic NSCLC and EGFR mutations receiving first‐line EGFR–TKI treatment revealed that combining denosumab with EGFR–TKI leads to longer OS than EGFR–TKI monotherapy.20 Here, EGFR is linked to non-small cell lung carcinoma.